According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- the published epitope mapping, structural studies, and sequence analyses which defendants had used to claim ADG20 was effective against the COVID-19 (formerly referred to as severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2) Omicron variant (“Omicron”) were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron;
- claims regarding ADG20’s efficacy against Omicron lacked a reasonable factual basis;
- ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants; and
- as a result, the Company’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.